369 related articles for article (PubMed ID: 34052871)
21. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
22. alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.
Bockenstedt PL; Santinga JT; Bolling SF
Am J Hematol; 1994 Mar; 45(3):248-51. PubMed ID: 8296798
[TBL] [Abstract][Full Text] [Related]
23. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
24. Practical approach to the patient with hypereosinophilia.
Roufosse F; Weller PF
J Allergy Clin Immunol; 2010 Jul; 126(1):39-44. PubMed ID: 20538328
[TBL] [Abstract][Full Text] [Related]
25. Approach to the patient with suspected hypereosinophilic syndrome.
Klion AD
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):47-54. PubMed ID: 36485140
[TBL] [Abstract][Full Text] [Related]
26. Clinical and histopathological features of hypereosinophilic syndrome with cutaneous involvement: The Mayo Clinic Experience.
Zayas J; Peters MS; Butterfield JH; Pongdee T; Sokumbi O
J Cutan Pathol; 2023 May; 50(5):455-465. PubMed ID: 36790036
[TBL] [Abstract][Full Text] [Related]
27. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
28. Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemias.
Valent P; Horny HP; Bochner BS; Haferlach T; Reiter A
Semin Hematol; 2012 Apr; 49(2):171-81. PubMed ID: 22449627
[TBL] [Abstract][Full Text] [Related]
29. Evaluation and Differential Diagnosis of Persistent Marked Eosinophilia.
Curtis C; Ogbogu PU
Immunol Allergy Clin North Am; 2015 Aug; 35(3):387-402. PubMed ID: 26209891
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Biological Markers in Hypereosinophilic Syndromes.
Khoury P; Makiya M; Klion AD
Front Med (Lausanne); 2017; 4():240. PubMed ID: 29312946
[TBL] [Abstract][Full Text] [Related]
31. Idiopathic Hypereosinophilic Syndrome in an Elderly Female: A Case Report.
Khalid F; Holguin F
Am J Case Rep; 2019 Mar; 20():381-384. PubMed ID: 30902963
[TBL] [Abstract][Full Text] [Related]
32. New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states.
Berki T; Dávid M; Bóné B; Losonczy H; Vass J; Németh P
Pathol Oncol Res; 2001; 7(4):292-7. PubMed ID: 11882909
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.
Valent P; Gleich GJ; Reiter A; Roufosse F; Weller PF; Hellmann A; Metzgeroth G; Leiferman KM; Arock M; Sotlar K; Butterfield JH; Cerny-Reiterer S; Mayerhofer M; Vandenberghe P; Haferlach T; Bochner BS; Gotlib J; Horny HP; Simon HU; Klion AD
Expert Rev Hematol; 2012 Apr; 5(2):157-76. PubMed ID: 22475285
[TBL] [Abstract][Full Text] [Related]
34. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular manifestations of hypereosinophilic syndromes.
Ogbogu PU; Rosing DR; Horne MK
Immunol Allergy Clin North Am; 2007 Aug; 27(3):457-75. PubMed ID: 17868859
[TBL] [Abstract][Full Text] [Related]
36. Marked and persistent eosinophilia in the absence of clinical manifestations.
Chen YY; Khoury P; Ware JM; Holland-Thomas NC; Stoddard JL; Gurprasad S; Waldner AJ; Klion AD
J Allergy Clin Immunol; 2014 Apr; 133(4):1195-202. PubMed ID: 23987798
[TBL] [Abstract][Full Text] [Related]
37. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
[TBL] [Abstract][Full Text] [Related]
38. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
39. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Requena G; van den Bosch J; Akuthota P; Kovalszki A; Steinfeld J; Kwon N; Van Dyke MK
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2125-2134. PubMed ID: 35470096
[TBL] [Abstract][Full Text] [Related]
40. Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.
Yamada Y; Rothenberg ME; Cancelas JA
Transl Oncogenomics; 2006; 1():53-63. PubMed ID: 23662039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
